Peringatan Keamanan

The most common symptoms of streptomycin overdose are ototoxicity and vestibular impairment.A233320 Streptomycin is also associated with nephrotoxicity which presents as mild elevations in blood urea, mild proteinuria, and excess cellular excretion. While in severe cases, streptomycin may lead to permanent hearing loss and vestibular dysfunction, any associated nephrotoxicity is typically transient.A233320,A233385 In cases of toxicity, streptomycin serum concentrations may be lowered with dialysis.A233320

Streptomycin

DB01082

small molecule approved vet_approved

Deskripsi

Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s.A233325,A233390 Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.A233325,A232294 Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.A233325

Struktur Molekul 2D

Berat 581.5741
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Streptomycins serum half-life is estimated to be 2.5 hours.[A233320]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Due to poor oral absorption, aminoglycosides including streptomycin are administered parenterally. Streptomycin is available as an intramuscular injection, and in some cases may be administered intravenously.A233320,A233325 A peak serum concentration of 25-50 mcg/mL is achieved within 1 hour after intramuscular administration of 1 gram of streptomycin.L33224

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Approximately 50% of streptomycin is eliminated in the urine within 24 hours after intravenous or intramuscular administration.A233734

Interaksi Obat

922 Data
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Streptomycin.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Streptomycin.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Streptomycin.
Cisatracurium Streptomycin may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Streptomycin.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Streptomycin.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Streptomycin.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Streptomycin.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Streptomycin.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Streptomycin.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Streptomycin.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Streptomycin.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Streptomycin.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Streptomycin.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Streptomycin.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Streptomycin.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Streptomycin.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Streptomycin.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Streptomycin.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Streptomycin.
Carboplatin The risk or severity of ototoxicity and nephrotoxicity can be increased when Streptomycin is combined with Carboplatin.
Foscarnet The risk or severity of nephrotoxicity can be increased when Streptomycin is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Streptomycin.
Tenofovir disoproxil Streptomycin may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Streptomycin.
Tenofovir Streptomycin may increase the nephrotoxic activities of Tenofovir.
Zoledronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Zoledronic acid.
Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Alendronic acid.
Ibandronate The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Ibandronate.
Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Clodronic acid.
Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Risedronic acid.
Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Etidronic acid.
Incadronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Incadronic acid.
Taxifolin The risk or severity of nephrotoxicity can be increased when Taxifolin is combined with Streptomycin.
Licofelone The risk or severity of nephrotoxicity can be increased when Licofelone is combined with Streptomycin.
Polmacoxib The risk or severity of nephrotoxicity can be increased when Polmacoxib is combined with Streptomycin.
Ebselen The risk or severity of nephrotoxicity can be increased when Ebselen is combined with Streptomycin.
Flurbiprofen axetil The risk or severity of nephrotoxicity can be increased when Flurbiprofen axetil is combined with Streptomycin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Streptomycin is combined with Acetyldigitoxin.
Deslanoside The risk or severity of adverse effects can be increased when Streptomycin is combined with Deslanoside.
Ouabain The risk or severity of adverse effects can be increased when Streptomycin is combined with Ouabain.
Digitoxin The risk or severity of adverse effects can be increased when Streptomycin is combined with Digitoxin.
Oleandrin The risk or severity of adverse effects can be increased when Streptomycin is combined with Oleandrin.
Cymarin The risk or severity of adverse effects can be increased when Streptomycin is combined with Cymarin.
Proscillaridin The risk or severity of adverse effects can be increased when Streptomycin is combined with Proscillaridin.
Metildigoxin The risk or severity of adverse effects can be increased when Streptomycin is combined with Metildigoxin.
Lanatoside C The risk or severity of adverse effects can be increased when Streptomycin is combined with Lanatoside C.
Gitoformate The risk or severity of adverse effects can be increased when Streptomycin is combined with Gitoformate.
Acetyldigoxin The risk or severity of adverse effects can be increased when Streptomycin is combined with Acetyldigoxin.
Peruvoside The risk or severity of adverse effects can be increased when Streptomycin is combined with Peruvoside.
Torasemide The serum concentration of Streptomycin can be increased when it is combined with Torasemide.
Bumetanide The serum concentration of Streptomycin can be increased when it is combined with Bumetanide.
Etacrynic acid The serum concentration of Streptomycin can be increased when it is combined with Etacrynic acid.
Piretanide The serum concentration of Streptomycin can be increased when it is combined with Piretanide.
Azosemide The serum concentration of Streptomycin can be increased when it is combined with Azosemide.
Tripamide The serum concentration of Streptomycin can be increased when it is combined with Tripamide.
Flucloxacillin The serum concentration of Streptomycin can be decreased when it is combined with Flucloxacillin.
Phenoxymethylpenicillin The serum concentration of Streptomycin can be decreased when it is combined with Phenoxymethylpenicillin.
Dicloxacillin The serum concentration of Streptomycin can be decreased when it is combined with Dicloxacillin.
Carbenicillin The serum concentration of Streptomycin can be decreased when it is combined with Carbenicillin.
Nafcillin The serum concentration of Streptomycin can be decreased when it is combined with Nafcillin.
Hetacillin The serum concentration of Streptomycin can be decreased when it is combined with Hetacillin.
Benzylpenicilloyl polylysine The serum concentration of Streptomycin can be decreased when it is combined with Benzylpenicilloyl polylysine.
Mezlocillin The serum concentration of Streptomycin can be decreased when it is combined with Mezlocillin.
Cyclacillin The serum concentration of Streptomycin can be decreased when it is combined with Cyclacillin.
Benzylpenicillin The serum concentration of Streptomycin can be decreased when it is combined with Benzylpenicillin.
Azlocillin The serum concentration of Streptomycin can be decreased when it is combined with Azlocillin.
Cloxacillin The serum concentration of Streptomycin can be decreased when it is combined with Cloxacillin.
Amdinocillin The serum concentration of Streptomycin can be decreased when it is combined with Amdinocillin.
Bacampicillin The serum concentration of Streptomycin can be decreased when it is combined with Bacampicillin.
Meticillin The serum concentration of Streptomycin can be decreased when it is combined with Meticillin.
Pivampicillin The serum concentration of Streptomycin can be decreased when it is combined with Pivampicillin.
Pivmecillinam The serum concentration of Streptomycin can be decreased when it is combined with Pivmecillinam.
Ticarcillin The serum concentration of Streptomycin can be decreased when it is combined with Ticarcillin.
Azidocillin The serum concentration of Streptomycin can be decreased when it is combined with Azidocillin.
Carindacillin The serum concentration of Streptomycin can be decreased when it is combined with Carindacillin.
Sultamicillin The serum concentration of Streptomycin can be decreased when it is combined with Sultamicillin.
Temocillin The serum concentration of Streptomycin can be decreased when it is combined with Temocillin.
Epicillin The serum concentration of Streptomycin can be decreased when it is combined with Epicillin.
Pheneticillin The serum concentration of Streptomycin can be decreased when it is combined with Pheneticillin.
Carfecillin The serum concentration of Streptomycin can be decreased when it is combined with Carfecillin.
Propicillin The serum concentration of Streptomycin can be decreased when it is combined with Propicillin.
Clometocillin The serum concentration of Streptomycin can be decreased when it is combined with Clometocillin.
Sulbenicillin The serum concentration of Streptomycin can be decreased when it is combined with Sulbenicillin.
Penamecillin The serum concentration of Streptomycin can be decreased when it is combined with Penamecillin.
Talampicillin The serum concentration of Streptomycin can be decreased when it is combined with Talampicillin.
Aspoxicillin The serum concentration of Streptomycin can be decreased when it is combined with Aspoxicillin.
Metampicillin The serum concentration of Streptomycin can be decreased when it is combined with Metampicillin.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Streptomycin.
Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Streptomycin.
Lymecycline The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Streptomycin.
Clomocycline The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Streptomycin.
Quinine The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Streptomycin.
Tigecycline The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Streptomycin.
Oxytetracycline The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Streptomycin.
Demeclocycline The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Streptomycin.
Magnesium sulfate The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Streptomycin.
Metacycline The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Streptomycin.
Minocycline The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Streptomycin.
Clindamycin The risk or severity of neuromuscular blockade can be increased when Streptomycin is combined with Clindamycin.

Target Protein

16S ribosomal RNA
23S ribosomal RNA
30S ribosomal protein S12 rpsL
Cytoplasmic membrane
Bacterial outer membrane
Protein-arginine deiminase type-4 PADI4

Referensi & Sumber

Synthesis reference: Arnold L. Demain, Kozo Nagaoka, "Derivatives of streptomycin and method of producing streptomycin derivatives by mutational biosynthesis." U.S. Patent US3993544, issued November 23, 1976.
Artikel (PubMed)
  • PMID: 31082149
    Block M, Blanchard DL: Aminoglycosides .
  • PMID: 32310346
    Waters M, Tadi P: Streptomycin .
  • PMID: 31643557
    Authors unspecified: Aminoglycosides .
  • PMID: 27386243
    Adeyemo AA, Oluwatosin O, Omotade OO: Study of streptomycin-induced ototoxicity: protocol for a longitudinal study. Springerplus. 2016 Jun 17;5(1):758. doi: 10.1186/s40064-016-2429-5. eCollection 2016.
  • PMID: 30993373
    Laurell G: Pharmacological intervention in the field of ototoxicity. HNO. 2019 Jun;67(6):434-439. doi: 10.1007/s00106-019-0663-1.
  • PMID: 30447062
    Serio AW, Keepers T, Andrews L, Krause KM: Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation. EcoSal Plus. 2018 Nov;8(1). doi: 10.1128/ecosalplus.ESP-0002-2018.
  • PMID: 16695303
    Buggs CW, Pilling MA, Bronstein B, Hirshfeld JW, Worzniak L, Key LJ: THE ABSORPTION, DISTRIBUTION, AND EXCRETION OF STREPTOMYCIN IN MAN. J Clin Invest. 1946 Jan;25(1):94-102. doi: 10.1172/JCI101693.
  • PMID: 3013085
    Moore RA, Bates NC, Hancock RE: Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob Agents Chemother. 1986 Mar;29(3):496-500. doi: 10.1128/aac.29.3.496.
Menampilkan 8 dari 18 artikel.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Streptomycin
    Injection, powder, lyophilized, for solution • 1 g/1 • Intramuscular • US • Generic • Approved
  • Streptomycin for Injection USP
    Powder, for solution • 1 g / vial • Intramuscular • Canada • Approved
  • Streptomycin Sulfate
    Injection, solution • 1 g/2.5mL • Intramuscular • US • Generic • Approved
  • Streptomycin Sulfate Injection USP 1g/2.5ml
    Liquid • 1 g / 2.5 mL • Intramuscular • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul